Abstract:IMPORTANCE Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with diabetes mellitus (DM). OBJECTIVE To conduct ameta-analysis to separately evaluate the effects of ACEIs and ARBs on all-cause mortality, CV deaths, and major CV events in patients with DM. DATA SOURCES Data sources included MEDLINE (1966-2012), EMBASE (1988-2012), the Cochrane Central Register of Controlled Trials, conference proceedings, and article reference lists. STUDY SELECTION We included randomized clinical trials reporting the effects of ACEI and ARB regimens for DM on all-cause mortality, CV deaths, and major CV events with an observation period of at least 12 months. Studies were excluded if they were crossover trials. DATA EXTRACTION AND SYNTHESIS Dichotomous outcome data from individual trials were analyzed using the risk ratio (RR) measure and its 95% CI with random-effects models. We estimated the difference between the estimates of the subgroups according to tests for interaction. We performed meta-regression analyses to identify sources of heterogeneity. MAIN OUTCOMES AND MEASURES Primary end points were all-cause mortality and death from CV causes. Secondary end points were the effects of ACEIs and ARBs on major CV events. RESULTS Twenty-three of 35 identified trials compared ACEIs with placebo or active drugs (32 827 patients) and 13 compared ARBs with no therapy (controls) (23 867 patients). When compared with controls (placebo/active treatment), ACEIs significantly reduced the risk of all-cause mortality by 13%(RR, 0.87; 95% CI, 0.78-0.98), CV deaths by 17%(0.83; 0.70-0.99), and major CV events by 14%(0.86; 0.77-0.95), including myocardial infarction by 21% (0.79; 0.65-0.95) and heart failure by 19% (0.81; 0.71-0.93). Treatment with ARBs did not significantly affect all-cause mortality (RR, 0.94; 95% CI, 0.82-1.08), CV death rate (1.21; 0.81-1.80), and major CV events (0.94; 0.85-1.01) with the exception of heart failure (0.70; 0.59-0.82). Both ACEIs and ARBs were not associated with a decrease in the risk for stroke in patients with DM. Meta-regression analysis showed that the ACEI treatment effect on all-cause mortality and CV death did not vary significantly with the starting baseline blood pressure and proteinuria of the trial participants and the type of ACEI and DM. CONCLUSIONS AND RELEVANCE Angiotensin-converting enzyme inhibitors reduced all-cause mortality, CV mortality, and major CV events in patients with DM, whereas ARBs had no benefits on these outcomes. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.

Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in type 2 diabetic patients.

Improvement in Endothelial Progenitor Cells from Peripheral Blood by Ramipril Therapy in Patients with Stable Coronary Artery Disease

Perindopril Improves Endothelial Progenitor Cell Mobilization in Diabetic Rats After Acute Myocardial Infarction

Worse Clinical Outcomes In Acute Myocardial Infarction Patients With Type 2 Diabetes Mellitus: Relevance To Impaired Endothelial Progenitor Cells Mobilization

Perindopril attenuates renal tubulointerstitium injury by inhibiting scavenger receptor A over-expression in diabetic rats

Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes

Effects of Perindopril on cardiomyopathy of diabetic rats and the expression of TGF-β_1

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.

Amlodipine Improves Endothelial Progenitor Cell Mobilization and Neo-vascularization in Experimental Diabetic Rats After Myocardial Infarction

INCREASE MIGRATION OF PERIPHERAL BLOOD DERIVED ENDOTHELIAL PROGENITOR CELLS OF STABLE CORONARY ARTERY DISEASE PATIENT WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS

Adiponectin-Transfected Endothelial Progenitor Cells Have Protective Effects After 2-Hour Middle-Cerebral Artery Occlusion in Rats With Type 2 Diabetes Mellitus

Impaired Mobilization of Bone-Derived Endothelial Progenitor Cells in Patients of Acute Myocardial Infarction with Type 2 Diabetics

Effects Of Angiotensin-Converting Enzyme Inhibition And Bradykinin Peptides In Rats With Myocardial Infarction

Effects of Angiotensin II Receptor Blocker on Myocardial Endothelial-to-mesenchymal Transition in Diabetic Rats

Cardiac-derived Adiponectin Induced by Long-Term Insulin Treatment Ameliorates Myocardial Ischemia/reperfusion Injury in Type 1 Diabetic Mice Via AMPK Signaling

A randomized controlled trial of the effects of non-surgical periodontal therapy on cardiac function assessed by echocardiography in type 2 diabetic patients

Cardioprotective Effects of Tanshinone IIA Pretreatment Via Kinin B2 Receptor-Akt-gsk-3β Dependent Pathway in Experimental Diabetic Cardiomyopathy

A cohort study of circulating progenitor cells after ST-segment elevation and non-ST segment elevation myocardial infarction in non-diabetic and diabetic patients

Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention

Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats Through Endothelial Progenitor Cell Mobilization

Effect Of Combined Treatment With Rosuvastatin And Protein Kinase C Beta 2 Inhibitor On Angiogenesis Following Myocardial Infarction In Diabetic Rats